WO1992012959A1 - Amide derivatives and their therapeutic use - Google Patents
Amide derivatives and their therapeutic use Download PDFInfo
- Publication number
- WO1992012959A1 WO1992012959A1 PCT/GB1992/000108 GB9200108W WO9212959A1 WO 1992012959 A1 WO1992012959 A1 WO 1992012959A1 GB 9200108 W GB9200108 W GB 9200108W WO 9212959 A1 WO9212959 A1 WO 9212959A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- formula
- cyclopropyl
- butenamide
- physiologically functional
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/02—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
- C07C233/11—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
Definitions
- the present invention relates to 3-phenyl-2-alkenamide derivatives, physiologically functional derivatives thereof, pharmaceutical preparations containing them and the use of such compounds and preparations in therapy, particularly as muscle relaxants, anxiolytics and anti-convulsants.
- European patent specification no. 0381508 describes the use of certain cinnamamides for relaxing muscle tone, for example, in the treatment of muscle spasm or spastic paralysis such as cerebral injuries.
- a neosin containing a satuticaally effective muscle relaxants and anticonvulsants are the induction of sedation and incoordination in the recipient, which severely limits the usefulness of these compounds.
- Similar side effects have been found with drugs used in the treatment of anxiety, such as, benzodiazepines. Although these effects may be transient, patients on such therapy are often unable to drive or participate in certain occupations.
- R 1 represents C 1-6 alkyl
- R 2 represents hydrogen or C 3-6 cycloalkyl
- R 3 represents one or more ring substituents selected from halogen (for example, Cl,Br,I,F) and perhaloC 1-4 alkyl (for, example trifluoromethyl); with the following provisos that:
- said compound of formula (I) is not 3-(4-chlorophenyl)-2-butenamide; or a base salt or other physiologically functional derivative thereof.
- alkyl as a group or part of a group means a straight or branched chain alkyl group. Such alkyl groups preferably have 1 to 3 carbon atoms and are more preferably methyl or ethyl, most preferably methyl.
- Preferred compounds of formula (I) include those wherein R 1 represents methyl and/or, R 2 represents cyclopropyl and/or the or one of R 3 is a ring substituent at the 2-position, preferably bromo, chloro or iodo or a perhalomethyl, for example trifluoromethyl; or a base salt or other physiologically functional derivative thereof.
- Particularly preferred compounds of formula (I) include those wherein
- R 1 represents methyl and/or, R 2 represents cyclopropyl and/or R 3 is a single ring substituent at the 2-position, preferably bromo, chloro, iodo or trifluoromethyl; or a base salt or other physiologically functional derivative thereof.
- the compounds of formula (I) above and their base salts, or other physiologically functional derivatives are hereinafter referred to as the compounds according to the invention. It will be appreciated that the compounds of formula (I) may exist in various geoisomeric forms and as mixtures thereof in any proportions. The present invention includes within its scope the use of such geoisomeric forms or mixtures of geoisomers, including the individual E and Z isomers of the compounds of formula (I) as well as mixtures of such isomers, in any proportions.
- base salts according to the invention include salts, for example, derived from an appropriate base, such as alkali metal (e.g. sodium), alkaline earth metal (e.g. magnesium) salts, ammonium and NX 4 + (wherein X is C 1-4 alkyl).
- alkali metal e.g. sodium
- alkaline earth metal e.g. magnesium
- ammonium e.g. ammonium
- NX 4 + wherein X is C 1-4 alkyl
- salts of compounds of formula (I) will be physiologically acceptable, i.e. they will be salts derived from a physiologically acceptable base.
- salts of bases which are not physiologically acceptable may also find use, for example in the preparation or purification of the compound. All base salts whether or not derived from a physiologically acceptable base are to be considered as being within the scope of the present invention.
- the compounds are thus of particular value in the relaxation of skeletal muscle in spastic, hypertonic and hyperkinetic conditions.
- the compounds may be used in the treatment and symptomatic relief of conditions such as spinal cord injury, parkinsonism, chorea, arthritis, athetosis, status epilepticus and tetanus and especially in the relief of muscle spasm in conditions such as myositis, spondylitis, cerebral palsy, cerebrovascular disease amd multiple sclerosis.
- the compounds may also be used for the treatment of exertion-induced skeletal muscle spasm, for example, lower back pain.
- Convulsive states for which the compounds may be employed include grand mal, petit mal, psychomotor epilepsy and focal seizure.
- the compounds according to the invention may also be used in the treatment of anxiety including generalised anxiety disorders, obsessive compulsive disorder, panic disorder, phobic anxiety, separation anxiety and post-traumatic stress disorder.
- a further use of such compounds is as presurgical muscle relaxants and anti-anxiety agents.
- a compound according to the invention in the manufacture of a medicament for the treatment or prophylaxis of conditions associated with abnormally raised muscle tone, convulsive states or anxiety.
- the above compounds according to the invention may be employed in combination with other therapeutic agents for the treatment of the conditions associated with abnormally raised muscle tone.
- therapeutic agents include analgesics, such as, codeine, acetaminophen, phenacetin or ibuprofen.
- the present invention further provides pharmaceutical formulations of the compounds according to the invention, also referred to herein as active ingredients, which may be administered for therapy by any suitable route including oral, rectal, nasal, topical (including buccal and sublingual), vaginal and parenteral (including subcutaneous, intramuscular, intravenous and intradermal). It will also be appreciated that the preferred route will vary with the conditions and age of the recipient, the nature of the disorder and the chosen active ingredient.
- a suitable dose of a compound of formula (I) or a base salt or other physiologically functional derivatives thereof is in the range of 0.05 to 100mg per kilogram body weight of the recipient per day, preferably in the range of 0.1 to 50mg per kilogram body weight per day, most preferably in the range 0.5 to 20mg per kilogram body weight per day and optimally 3mg per kilogram body weight per day.
- the desired dose is preferably presented as two, three, four, five, six or more sub-doses administered at appropriate intervals throughout the day.
- sub-doses may be administered in unit dosage forms, for example, containing 1 to 1500mg, preferably 5 to 1000mg, and most preferably 10 to 700mg of active ingredient per unit dosage form. While it is possible for the active ingredient to be administered alone it is preferable to present it as a pharmaceutical formulation.
- the formulations of the present invention comprises at least one active ingredient, as defined above, together with one or more acceptable carriers thereof and optionally other therapeutic agents. Each carrier must be "acceptable” in the sense of being compatible with the other ingredients of the formulation and not injurious to the patient.
- Formulations include those suitable for oral, rectal, nasal, topical (including buccal and sublingual), vaginal or parenteral (including subcutaneous, intramuscular, intravenous and intradermal) administration.
- the formulations may conveniently be presented in unit dosage form and may be prepared by any methods well known in the art of pharmacy. Such methods include the step of bringing into association the active ingredient with the carrier which constitutes one or more accessory ingredients.
- the formulations are prepared by uniformly and intimately bringing into association the active ingredient with liquid carriers or finely divided solid carriers or both, and then if necessary shaping the product.
- Formulations of the present invention suitable for oral administration may be presented as discrete units such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient; as a powder or granules; as a solution or suspension in an aqueous or non-aqueous liquid; or as an oil-in-water liquid emulsion or a water-in-oil liquid emulsion.
- the active ingredient may also be presented as a bolus, electuary or paste.
- a tablet may be made by compression or molding, optionally with one or more accessory ingredients.
- Compressed tablets may be prepared by compressing in a suitable machine the active ingredient in a free-flowing form such as a powder or granules, optionally mixed with a binder (e.g. povidone, gelatin, hydroxypropylmethyl cellulose), lubricant, inert diluent, preservative, disintegrant (e.g. sodium starch glycollate, cross-linked povidone, cross-linked sodium carboxymethyl cellulose) surface-active or dispersing agent.
- Molded tablets may be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent.
- the tablets may optionally be coated or scored and may be formulated so as to provide slow or controlled release of the active ingredient therein using, for example hydroxypropylmethyl cellulose in varying proportions to provide the desired release profile. Tablets may optionally be provided with an enteric coating, to provide release in parts of the gut other than the stomach.
- Formulations suitable for oral use as described above may also include buffering agents designed to neutralize stomach acidity.
- buffers may be chosen from a variety of organic or inorganic agents such as weak acids or bases admixed with their conjugated salts.
- Formulations suitable for topical administration in the mouth include lozenges comprising the active ingredient in a flavored basis, usually sucrose and acacia or tragacanth; pastilles comprising the active ingredient in an inert basis such as gelatin and glycerin, or sucrose and acacia; and mouthwashes comprising the active ingredient in a suitable liquid carrier.
- Formulations for rectal administration may be presented as a suppository with a suitable base comprising for example cocoa butter or a salicylate.
- Formulations suitable for vaginal administration may be presented as pessaries, tampons, creams, gels pastes, foams or spray formulations containing in addition to the active ingredient such carriers as are known in the art to be appropriate.
- Formulations suitable for parenteral administration include aqueous and non-aqueous isotonic sterile injections solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents, as liposomes or other microparticulate systems which are designed to target the compounds to blood components or one or more organs.
- the formulations may be presented in unit-dose or multi-dose sealed containers, for example, ampoules and vials, and may be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example water for injections, immediately prior to use.
- Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets of the kind previously described.
- Formulations suitable for transdermal administration may be presented as discrete patches adapted to remain in intimate contact with the epidermis of the recipient for a prolonged period of time.
- patches suitably contain the active compound as an optionally buffered, aqueous solution of, for example, 0.1 to 0.2M concentration with respect to the said compound.
- the active compound may be delivered from the patch by iontophoresis as generally described in Pharmaceutical Research, 3/6, 318 (1986).
- Preferred unit dosage formulations are those containing a daily dose or unit, daily sub-dose, as herein above recited, or an appropriate fraction thereof, of an active ingredient.
- formulations of this invention may include other agents conventional in the art having regard to the type of formulation in question, for example, those suitable for oral administration may include such further agents as sweeteners, thickeners and flavoring agents.
- suitable for oral administration may include such further agents as sweeteners, thickeners and flavoring agents.
- the compounds of formula (I) may be prepared in any conventional manner and in accordance with the present invention, may, for example, be prepared by any method hereinafter described.
- the present invention further includes a process for the preparation of compounds of formula (I) and base salts, and other physiologically functional derivatives thereof which comprises:-
- R 3 is as hereinbefore defined and X is a suitable leaving group, for example a halogen atom such as bromine or iodine or a sulphonate such as CF 3 S(O) 2 O- with a compound of formula (III)
- R 1 and R 3 are as hereinbefore defined and Z is a suitable leaving group, for example, a halogen atom, such as bromine or chlorine, azido, amino, or a ROC(O)O- group wherein R represents C 1-6 alkyl, for example, CH 3 CH- 2 OC(O)O- or an alkanoyloxy group, such as acetyloxy) with a compound of formula
- a compound of formula (II) is reacted with a compound of formula (III), typically in the presence of a catalyst, such as a transition metal catalyst, for example, a palladium catalyst, in particular, palladium acetate, conveniently in the presence of an organic base such as triethylamine (TEA) and in a suitable polar solvent, for example, acetonitrile, dimethylformamide (DMF) or methanol, preferably at an elevated temperature.
- a catalyst such as a transition metal catalyst, for example, a palladium catalyst, in particular, palladium acetate
- an organic base such as triethylamine (TEA)
- TAA triethylamine
- a suitable polar solvent for example, acetonitrile, dimethylformamide (DMF) or methanol, preferably at an elevated temperature.
- a phosphorus reagent such as tri-o-toluyl phosphine or another triarylphosphine.
- a compound of formula (IV) is reacted with a Wittig reagent of formula (V), generally in the presence of a strong base such as sodium hydride or lithium hydride and conveniently in an inert solvent, for example, dimethoxyethane (DME).
- a strong base such as sodium hydride or lithium hydride
- DME dimethoxyethane
- the relative proportions of E and Z isomers in the compound of formula (I) so formed will depend on the nature of the alkyl, aryl or aralkyl group In the phosphorus-containing group of the Wittig reagent.
- Compounds of formula (V) where Y and R 4 are as hereinbefore defined may be prepared by methods well known in the art, but are typically prepared from compounds of formula (V) wherein R 4 is as hereinbefore defined and Y is a suitable leaving group, for example, a halogen atom, such as chlorine or bromine, by treatment with a suitable phosphorylating agent such as a trialkylphosphite or a triarylphosphine.
- Compounds of formula (V) wherein R 4 is as hereinbefore defined and Y is a leaving group may be prepared from compounds of formula (V) wherein Y is the aforementioned leaving group and R 4 is another suitable leaving group, for example a halogen atom such as chlorine or bromine.
- Such compounds, for example, ClCOCH 2 Cl may be obtained from commercial sources or prepared by methods known to a skilled person or readily available from the chemical literature.
- dehydration of a compound of formula (VII) may be effected with a suitable dehydrating agent, such as acetic anhydride, typically in the presence of an acid such as o.-toluenesulphonic acid.
- a suitable dehydrating agent such as acetic anhydride
- (VII) obtained may be isolated or dehydrated in situ.
- Process D) may be carried out by treating a compound of formula (VIII) with a compound of formula (IX), typically in an inert solvent such as THF or benzene.
- Z is to be halogen, by treatment with a halogenating agent such as oxalyl chloride in an inert solvent such as benzene or, where Z is to be a ROC(O)O- group wherein R is as hereinbefore defined, by treatment with the appropriate alkylchloroformate in the presence of an organic base such as TEA and in an inert solvent such as THF.
- a halogenating agent such as oxalyl chloride in an inert solvent such as benzene or, where Z is to be a ROC(O)O- group wherein R is as hereinbefore defined
- the compound of formula (VIII) obtained may be isolated or aminated in situ.
- Such compounds may be prepared by the Reformatski reaction described in process C) above.
- the compound of formula (I) may be converted into a pharmaceutically acceptable base salt in a conventional manner, for example, by treatment with the appropriate base.
- the present invention further includes the following novel intermediates which are of particular value for the preparation of compounds of formula (I) wherein R 1 and R 2 are as hereinbefore defined and R 3 is 2-bromo:-
- Ethyl chloroformate (Aldrich) (0.13g, 1.24mmol) was added dropwise to a stirred solution of (E)-3-(2-bromophenyl)-2-butenoic acid (0.30g, 1.24mmol), triethylamine (0.12g, 1.24mmol) and tetrahydrofuran (5mL) at 0oC.
- the precipitated triethylamine hydrochloride was removed by filtering and a solution of cyclopropylamine (71mg, 1.24mmol) in tetrahydrofuran (ImL) was added dropwise to the ice-cold filtrate.
- This compound was prepared in an analogous manner to that of Example 1 with the replacement of 2'-bromoacetophenone in Example 1C with 2'-(trifluoromethyl)acetophenone (Aldrich).
- the chromatography solutions that contained (E)-N-cyclopropyl-3-(2-(trifluoromethyl))-2-phenyl)-2-butenamide were spin evaporated in vacuo.
- the solid was collected and recrystallized from ethanol-water to give 0.74g (10%) of (E)-N-cyclopropyl-3-(2-(trifluoromethyl))phenyl)-2-butenamide, m.p.
- This compound was prepared in an analogous manner to that of Example 1 with the replacement of 2' -bromoacetophenone in Example 1C with 2',3'-(dichloro)acetophenone (Maybridge).
- the chromatography solutions that contained (E)-N-cyclopropyl-3-(2,3-dichlorophenyl)-2-butenamide were spin evaporated, and the solid was collected and dried; yield, 6.73g (47%), m.p.
- This compound was prepared in an analogous manner to that of Example 1 with the replacement of 2'-bromoacetophenone in Example 1C with 2'-chloroacetophenone (Aldrich).
- the chromatography solutions that contained (E)-3-(2-chlorophenyl)-N-cyclopropyl-2-butenamide were spin evaporated in vacuo. The solid was collected and dried; yield, 28.30g (32%), m.p.
- reaction mixture was spin evaporated in vacuo, and the residue was partitioned between ethyl acetate and 5% aqueous sodium bicarbonate.
- the ethyl acetate layer was washed with 1N hydrochloric acid and brine.
- the ethyl acetate solution was dried (sodium sulfate) and spin evaporated in vacuo.
- the residual yellow solid was purified by flash chromatography on silica gel 60 (40-63 m, E. Merck No. 9385) using ethyl acetate-hexane (1:4) as eluent.
- This compound was prepared in an analogous manner to that of Example 3 with the replacement of cyclopropylamine in Example 3C with cyclobutylamine (Aldrich). The solid was recrystallized from dichloromethane-hexanes to give off white crystals (1.1g, 64%) of the product, m.p.
- This compound was prepared (3.0 molar scale) in a manner analogous to that of Example 1B with the replacement of triethyl phosphite with triisopropylphosphite (Aldrich) and pentane with hexane: yield, 385g (48.7%) as a fluffy white solid, m.p. 58-60oC; the analytical sample was recrystallized from hexane.
- This compound was prepared in an analogous manner to that of Example 1 with (Aldrich) the replacement of 2'-bromoacetophenone in Example 1C with 2'-iodoacetophenone (Aldrich) and the replacement of diethyl((cyclopropylcarbamoyl)methyl)phosphonate with diisopropyl((cyclopropylcarbamoyl)methyl)phosphonate.
- the chromatography solutions that contained (E)-N-cyclopropyl-3-(2- iodophenyl)-2-butenamide were spin evaporated in vacuo.
- the "Active Ingredient” may be any compound of formula (I) or base salt or other physiologically functional derivative thereof, for example, compounds of Examples 1 to
- formulations A, B and C are prepared by wet granulation of the ingredients with a solution of povidone, followed by addition of magnesium stearate and compression.
- formulations D and E are prepared by direct compression of the admixed ingredients.
- the lactose in formulation E is of the direct compression type (Dairy Crest - "Zeparox").
- the formulation is prepared by wet granulation of the ingredients (below) with a solution of povidone followed by the addition of magnesium stearate and compression. mg/tablet
- a capsule formulation is prepared by admixing the ingredients of Formulation D in Example 15 above and filling into a two-part hard gelatin capsule.
- Formulation B (infra) is prepared in a similar manner.
- Capsules of formulation D are prepared by dispersing the active ingredient in the lecithin and arachis oil and filling the dispersion into soft, elastic gelatin capsules.
- controlled release capsule formulation Is prepared by extruding ingredients a, b and c using an extruder, followed by spheronization of the extrudate and drying. The dried pellets are then coated with release-controlling membrane (d) and filled into a two-piece, hard gelatin capsule.
- release-controlling membrane d
- the active ingredient is dissolved in 95% Ethanol and PEG 400 (1:1).
- the batch is then made up to volume with the water and filtered through a sterile micropore filter into a sterile 10 mL amber glass vial (type 1) and sealed with sterile closures and overseals.
- the active ingredient is dissolved in a mixture of the glycerol and most of the purified water.
- An aqueous solution of the sodium benzoate is then added to the solution, followed by addition of the sorbitol solution and finally the flavor.
- the volume is made up with purified water and mixed well.
- Witepsol H15 is melted in a steam-jacketed pan at 45°C maximum.
- the active ingredient is sifted through a 200 M sieve and added to the molten base with mixing, using a Silverson fitted with a cutting head, until smooth dispersion is achieved. Maintaining the mixture at 45oC, the remaining Witepsol H15 is added to the suspension and stirred to ensure a homogenous mix.
- the entire suspension is passed through a 250 M stainless steel screen and, with continuous stirring, is allowed to cool to 40oC. At a temperature of 38oC to 40°C, 2.02 g of the mixture is filled into suitable, 2 mL plastic molds. The suppositories are allowed to cool to room temperature.
- Muscle relaxant activity of compounds of formula (I) was determined using a Straub tail test based on that described by K.O. Ellis and
- the Straub tail test result is reported as an ED 50 in mg/'kg.
- the ED 50 is defined as the dose of compound administered, which prevents Straub tail in 50% of mice.
- the compound is administered by oral gavage (po) 60 min. prior to scoring.
- Antagonism of morphine-induced Straub tail reflects muscle relaxant efficacy while failure in the rotorod test reflects sedation and incoordination. Determination of the ratio of rotorod failure to antagonism of morphine-induced Straub tail is a means of assessing side effect liability of muscle relaxants (G.D. Novak, Drug Dev. Res., 2 , 233 (1982).
- Anticonvulsant activity of compounds of formula (I) was determined using a method described by Mehta et al., J.Med.Chem., 24, 465 (1981).
- the anticonvuisant activity is reported as an ED 50 in mg/kg.
- the ED 50 for protection against maximal electroshock-induced convulsions was the dose which prevented hind limb extension in 50% of the animals.
- the ED 50 for protection against Metrazol-induced convulsions was the dose which prevented? convulsions in 50% of the animals.
- Anxiolytic activity of the compounds according to the invention was measured using method of Geller and Seifter, J.Psychopharmacolgia, 1 , 482 (1960) as modified by Pollard and Howard, Psychopharmacology, 62, 117 (1979). Clinically efficacious anxiolytics increase punished responding. The anxiolytic activity of the compound is reported as the dose necessary to produce a 50% increase in punished responding in rats.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP4503564A JPH06506916A (en) | 1991-01-19 | 1992-01-17 | Amide derivatives and their therapeutic use |
AU11710/92A AU655000B2 (en) | 1991-01-19 | 1992-01-17 | Substituted (3) phenyl-2-butenamides their pharmaceutical applications and methods of preparation |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9101244.3 | 1991-01-19 | ||
GB919101244A GB9101244D0 (en) | 1991-01-19 | 1991-01-19 | Amide derivatives and their therapeutic use |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1992012959A1 true WO1992012959A1 (en) | 1992-08-06 |
Family
ID=10688745
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB1992/000108 WO1992012959A1 (en) | 1991-01-19 | 1992-01-17 | Amide derivatives and their therapeutic use |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP0569409A1 (en) |
JP (1) | JPH06506916A (en) |
AU (1) | AU655000B2 (en) |
CA (1) | CA2101783A1 (en) |
GB (1) | GB9101244D0 (en) |
HU (1) | HUT65231A (en) |
IE (1) | IE920138A1 (en) |
IL (1) | IL100689A0 (en) |
NZ (1) | NZ241331A (en) |
TW (1) | TW212170B (en) |
WO (1) | WO1992012959A1 (en) |
ZA (1) | ZA92357B (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995030644A1 (en) * | 1994-05-10 | 1995-11-16 | The Wellcome Foundation Limited | Amide derivatives and their therapeutic use |
EP0944581A1 (en) * | 1996-11-22 | 1999-09-29 | Eli Lilly And Company | Process of preparing substituted acrylamides |
EP3498273A1 (en) * | 2017-12-14 | 2019-06-19 | Universität Wien | Pharmaceutical composition for modulating the response of a gaba-a receptor |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6159943A (en) * | 1999-09-24 | 2000-12-12 | Bioenergy, Inc. | Use of ribose to prevent cramping and soreness in muscles |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2132547A1 (en) * | 1971-04-08 | 1972-11-24 | Clin Byla Ets | Substd phenyl alkyl or alkenyl amides - useful as analgesics and antiinflammatories |
US4190674A (en) * | 1976-02-03 | 1980-02-26 | Burroughs Wellcome Co. | 3-Fluoro-N-cyclopropylcinnamide |
EP0381508A2 (en) * | 1989-02-02 | 1990-08-08 | Taisho Pharmaceutical Co. Ltd | Use of cinnamamide for relaxing muscle tone |
-
1991
- 1991-01-19 GB GB919101244A patent/GB9101244D0/en active Pending
-
1992
- 1992-01-17 NZ NZ241331A patent/NZ241331A/en unknown
- 1992-01-17 IE IE013892A patent/IE920138A1/en not_active Application Discontinuation
- 1992-01-17 IL IL100689A patent/IL100689A0/en unknown
- 1992-01-17 CA CA002101783A patent/CA2101783A1/en not_active Abandoned
- 1992-01-17 HU HU9302052A patent/HUT65231A/en unknown
- 1992-01-17 TW TW081100323A patent/TW212170B/zh active
- 1992-01-17 ZA ZA92357A patent/ZA92357B/en unknown
- 1992-01-17 EP EP92903260A patent/EP0569409A1/en not_active Withdrawn
- 1992-01-17 JP JP4503564A patent/JPH06506916A/en active Pending
- 1992-01-17 WO PCT/GB1992/000108 patent/WO1992012959A1/en not_active Application Discontinuation
- 1992-01-17 AU AU11710/92A patent/AU655000B2/en not_active Ceased
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2132547A1 (en) * | 1971-04-08 | 1972-11-24 | Clin Byla Ets | Substd phenyl alkyl or alkenyl amides - useful as analgesics and antiinflammatories |
US4190674A (en) * | 1976-02-03 | 1980-02-26 | Burroughs Wellcome Co. | 3-Fluoro-N-cyclopropylcinnamide |
EP0381508A2 (en) * | 1989-02-02 | 1990-08-08 | Taisho Pharmaceutical Co. Ltd | Use of cinnamamide for relaxing muscle tone |
Non-Patent Citations (1)
Title |
---|
Journal of Medicinal Chemistry, vol. 9, no. 5, September 1966, (Washington, US), E. VAN HEYNINGEN: "N-monoalkyl-beta-alkylcinnamamides as sedatives", pages 675-681, see page 675; examples 16,18-20; table II (cited in the application) * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995030644A1 (en) * | 1994-05-10 | 1995-11-16 | The Wellcome Foundation Limited | Amide derivatives and their therapeutic use |
US5719186A (en) * | 1994-05-10 | 1998-02-17 | Glaxo Wellcome Inc. | Amide derivatives and their therapeutic use |
EP0944581A1 (en) * | 1996-11-22 | 1999-09-29 | Eli Lilly And Company | Process of preparing substituted acrylamides |
US6069247A (en) * | 1996-11-22 | 2000-05-30 | Eli Lilly And Company | Process for preparing substituted acrylamides by reaction of propiolamides and aromatic rings |
EP0944581A4 (en) * | 1996-11-22 | 2004-09-08 | Lilly Co Eli | Process of preparing substituted acrylamides |
EP3498273A1 (en) * | 2017-12-14 | 2019-06-19 | Universität Wien | Pharmaceutical composition for modulating the response of a gaba-a receptor |
Also Published As
Publication number | Publication date |
---|---|
TW212170B (en) | 1993-09-01 |
AU1171092A (en) | 1992-08-27 |
HU9302052D0 (en) | 1993-10-28 |
IL100689A0 (en) | 1992-09-06 |
NZ241331A (en) | 1994-08-26 |
JPH06506916A (en) | 1994-08-04 |
GB9101244D0 (en) | 1991-02-27 |
HUT65231A (en) | 1994-05-02 |
AU655000B2 (en) | 1994-12-01 |
EP0569409A1 (en) | 1993-11-18 |
IE920138A1 (en) | 1992-07-29 |
CA2101783A1 (en) | 1992-07-20 |
ZA92357B (en) | 1993-07-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2771328B2 (en) | N-phenylalkyl-substituted α-aminocarboxamide derivatives and method for producing the same | |
FI62821C (en) | PROCEDURE FOR THE PREPARATION OF THERAPEUTIC THERAPEUTIC HYDROXYSYROR | |
JPH093016A (en) | Novel aryl(alkyl)propylamide, its production, and medicine composition containing it | |
EP0699180B1 (en) | Bicyclic amide derivatives and their use as muscle relaxants | |
EP0257882A1 (en) | N-Phenyl butenamides with pharmaceutical properties | |
US5708033A (en) | Amide derivatives and their therapeutic use | |
WO1992012959A1 (en) | Amide derivatives and their therapeutic use | |
AU704261B2 (en) | Novel tricyclic amides, processes for their preparation and the pharmaceutical compositions which contain them | |
US5719186A (en) | Amide derivatives and their therapeutic use | |
US5708005A (en) | Quinolines, their production and use | |
KR100856141B1 (en) | Benzazepine derivatives as mao-b inhibitors | |
PL195667B1 (en) | Novel cyclic compounds compounds comprising a cycloalkylene chain, method of obtaining them and pharmaceutic compositions containing such compounds | |
JP3652721B2 (en) | Quinoline compounds | |
PT100196A (en) | Amide derivatives, process for their preparation and their therapeutic use | |
US6124284A (en) | Bicyclic amide derivatives and their use as muscle relaxants | |
FR2581996A1 (en) | NOVEL 6-SUBSTITUTED 6H-DIBENZO (B, D) THIOPYRANES DERIVATIVES USEFULLY IMMUNOMODULATORS AND ANTIVIRALS AND THEIR PREPARATION | |
JPH0157114B2 (en) | ||
JPS6233237B2 (en) | ||
AU684778C (en) | Bicyclic amide derivatives and their use as muscle relaxants | |
JPH0235748B2 (en) | OKISHIINDOORUJUDOTAI |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU BB BG BR CA CS FI HU JP KR LK NO RO RU US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IT LU MC NL SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1992903260 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 1993 87773 Country of ref document: US Date of ref document: 19930713 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2101783 Country of ref document: CA |
|
WWP | Wipo information: published in national office |
Ref document number: 1992903260 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 1995 382833 Country of ref document: US Date of ref document: 19950203 Kind code of ref document: A |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1992903260 Country of ref document: EP |